Tugba Akin Telli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tugba Akin Telli has a total of 416 co-authors. Here are the top co-authors by number of shared publications:
- Perran Fulden Yumuk
Division of Medical Oncology, Department of Internal Medicine, Koç University School of Medicine, İstanbul, Turkey
18 shared publications - Özkan Alan
Department of Medical Oncology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul 34098, Türkiye
14 shared publications Faysal Dane
Division of Medical Oncology, School of Medicine, Marmara University, Istanbul, Turkey
13 shared publications- Nazım Can Demircan
Marmara University School of Medicine
10 shared publications Ozlem Ercelep
Division of Medical Oncology, School of Medicine, Marmara University, Istanbul, Turkey
9 shared publicationsSerap Kaya
Department of Medical Oncology,Faculty of Medicine,Marmara University, Istanbul, Turkey
7 shared publications
Latest Publications
- Open Access
- 16 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 8979
First-Line Treatment and Survival in Women Aged ≥ 70 Years with De Novo Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Multicenter Cohort Study by the Turkish Oncology Group
Background: Real-world evidence regarding first-line treatment selection and clinical outcomes in women aged 70 years and older with de novo hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer remains limited. This study evaluated treatment patterns, survival outcomes, and treatment-related adverse events in this population. Methods: This multicenter retrospective study included 181 women aged ≥ 70 years with de novo HR+/HER2− metastatic breast cancer treated at 14 oncology centers in Türkiye between January 2016 and January 2026. Patients receiving first-line cyclin-dependent kinase 4/6 inhibitors plus aromatase inhibitors (CDK4/6i + AI; n = 136) were compared with those receiving other first-line regimens (n = 45). Treatment selection was evaluated using logistic regression, while progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier estimates and Cox regression. Results: CDK4/6i + AI was administered to 75.1% of patients. ECOG performance status ≥ 2 was independently associated with lower odds of receiving combination treatment (adjusted odds ratio [aOR], 0.24; p = 0.003), whereas higher baseline left ventricular ejection fraction was associated with greater treatment receipt (aOR per 5-percentage-point increase, 1.62; p = 0.002). Median PFS was significantly longer with CDK4/6i + AI than with other treatments (43.6 vs. 12.9 months; p < 0.001), and this association persisted after adjustment, including HER2 status (adjusted hazard ratio [aHR], 0.48; 95% CI, 0.27–0.86; p = 0.013). No significant OS difference was observed (48.9 vs. 46.1 months; p = 0.205). Neutropenia was more frequent with CDK4/6i + AI (70.6% vs. 31.1%; p < 0.001). Recorded renal adverse events were also more frequent (12.5% vs. 0%; p = 0.008), although these could not be reliably distinguished from isolated creatinine elevations. Conclusions: First-line CDK4/6i + AI therapy was associated with longer PFS, without a significant OS difference, in older women with de novo HR+/HER2− metastatic breast cancer. Treatment selection was associated with functional status and cardiac function, supporting individualized therapeutic decisions beyond chronological age.
- 16 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (22) , 8979
Open AccessFirst-Line Treatment and Survival in Women Aged ≥ 70 Years with De Novo Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Multicenter Cohort Study by the Turkish Oncology Group
Background: Real-world evidence regarding first-line treatment selection and clinical outcomes in women aged 70 years and older with de novo hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer remains limited. This study evaluated treatment patterns, survival outcomes, and treatment-related adverse events in this population. Methods: This multicenter retrospective study included 181 women aged ≥ 70 years with de novo HR+/HER2− metastatic breast cancer treated at 14 oncology centers in Türkiye between January 2016 and January 2026. Patients receiving first-line cyclin-dependent kinase 4/6 inhibitors plus aromatase inhibitors (CDK4/6i + AI; n = 136) were compared with those receiving other first-line regimens (n = 45). Treatment selection was evaluated using logistic regression, while progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan–Meier estimates and Cox regression. Results: CDK4/6i + AI was administered to 75.1% of patients. ECOG performance status ≥ 2 was independently associated with lower odds of receiving combination treatment (adjusted odds ratio [aOR], 0.24; p = 0.003), whereas higher baseline left ventricular ejection fraction was associated with greater treatment receipt (aOR per 5-percentage-point increase, 1.62; p = 0.002). Median PFS was significantly longer with CDK4/6i + AI than with other treatments (43.6 vs. 12.9 months; p < 0.001), and this association persisted after adjustment, including HER2 status (adjusted hazard ratio [aHR], 0.48; 95% CI, 0.27–0.86; p = 0.013). No significant OS difference was observed (48.9 vs. 46.1 months; p = 0.205). Neutropenia was more frequent with CDK4/6i + AI (70.6% vs. 31.1%; p < 0.001). Recorded renal adverse events were also more frequent (12.5% vs. 0%; p = 0.008), although these could not be reliably distinguished from isolated creatinine elevations. Conclusions: First-line CDK4/6i + AI therapy was associated with longer PFS, without a significant OS difference, in older women with de novo HR+/HER2− metastatic breast cancer. Treatment selection was associated with functional status and cardiac function, supporting individualized therapeutic decisions beyond chronological age.
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (3) , e2500655
Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO)
PURPOSE: Early-onset gastrointestinal cancers are concerning entities globally, yet early-onset biliary tract cancers (EOBTCs) are understudied. Early-stage disease is crucial for young patients' survival. METHODS: TOG/GI-SAFRADJU (ClinicalTrials.gov identifier: NCT06975917 ) is a multicenter, hospital-based, registry initiative of the Turkish Oncology Group, including patients with resected BTCs. Early-onset was defined as a diagnosis at age v 25.7%, P = .038). Adjuvant treatments did not differ between EOBTC and non-EOBTC. Among patients who received adjuvant chemotherapy, RFS (13.9 months [95% CI, 11.4 to 22.1] v 15.9 months [95% CI, 13.6 to 18.9], P = .947) and OS (35.6 months [95% CI, 28.0 to 81.4] v 31.3 months [95% CI, 27.8 to 44.3], P = .670) were similar between EOBTC and non-EOBTC groups. Among patients with EOBTC, R1-resection and high CA19-9 levels were associated with shorter RFS, and gallbladder localization and high CA19-9 were associated with shorter OS in adjusted analyses. Using these factors, risk scores early-stage EOBTC RFS score (EOB-RS) for RFS and early-stage EOBTC OS score (EOB-OS) for OS were formed, each including three ranks. Both scores significantly ordered the prognosis of patients with EOBTC (EOB-RS, [0 points]: 22.7 months, [1 or 2]: 10.3 months, [3]: 5.7 months, P < .001, EOB-OS: [0]: 110.9 months, [1 or 2]: 29.6 months, [3]: 10.1 months, P < .001). CONCLUSION: Resected EOBTC patients showed survival comparable to older counterparts receiving surgery/adjuvant therapy. This study suggests a potential risk scoring system for early-stage EOBTC, pending validation.
- 1 March 2026
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 12 (3) , e2500655
Resectable Stage Early-Onset Biliary Tract Cancer: Survival and Prognostic Scoring (EOB-RS and EOB-OS) in Turkish Patients (TOG/GI-SAFRADJU-2502-EO)
PURPOSE: Early-onset gastrointestinal cancers are concerning entities globally, yet early-onset biliary tract cancers (EOBTCs) are understudied. Early-stage disease is crucial for young patients' survival. METHODS: TOG/GI-SAFRADJU (ClinicalTrials.gov identifier: NCT06975917 ) is a multicenter, hospital-based, registry initiative of the Turkish Oncology Group, including patients with resected BTCs. Early-onset was defined as a diagnosis at age v 25.7%, P = .038). Adjuvant treatments did not differ between EOBTC and non-EOBTC. Among patients who received adjuvant chemotherapy, RFS (13.9 months [95% CI, 11.4 to 22.1] v 15.9 months [95% CI, 13.6 to 18.9], P = .947) and OS (35.6 months [95% CI, 28.0 to 81.4] v 31.3 months [95% CI, 27.8 to 44.3], P = .670) were similar between EOBTC and non-EOBTC groups. Among patients with EOBTC, R1-resection and high CA19-9 levels were associated with shorter RFS, and gallbladder localization and high CA19-9 were associated with shorter OS in adjusted analyses. Using these factors, risk scores early-stage EOBTC RFS score (EOB-RS) for RFS and early-stage EOBTC OS score (EOB-OS) for OS were formed, each including three ranks. Both scores significantly ordered the prognosis of patients with EOBTC (EOB-RS, [0 points]: 22.7 months, [1 or 2]: 10.3 months, [3]: 5.7 months, P < .001, EOB-OS: [0]: 110.9 months, [1 or 2]: 29.6 months, [3]: 10.1 months, P < .001). CONCLUSION: Resected EOBTC patients showed survival comparable to older counterparts receiving surgery/adjuvant therapy. This study suggests a potential risk scoring system for early-stage EOBTC, pending validation.
- 1 January 2026
- Published by Kare Publishing in Eurasian Journal of Medical Investigation
- Vol. 10 (3) , 337-344
Real-life Comparison of FOLFOX-6 and Modified DCF Regimens for the First-Line Treatment of HER-2 Negative Metastatic Gastric Cancer
Ejmi Eurasian Journal of Medical Investigation
- 1 January 2026
- Published by Kare Publishing in Eurasian Journal of Medical Investigation
- Vol. 10 (3) , 337-344
Real-life Comparison of FOLFOX-6 and Modified DCF Regimens for the First-Line Treatment of HER-2 Negative Metastatic Gastric Cancer
Ejmi Eurasian Journal of Medical Investigation
- 19 December 2025
- Published by Taylor & Francis in Journal of Chemotherapy
- p. 1-13
The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study
This multicentre real-world study evaluated the efficacy of targeted therapies in Turkish patients with metastatic squamous cell lung carcinoma harbouring driver mutations. Sixty-four patients with alterations such as EGFR, ALK, and ROS1 who received targeted agents were retrospectively analysed. EGFR mutations were most common (67.2%). Among EGFR-TKI-treated patients, median progression-free survival (PFS) and overall survival (OS) were 12.4 and 14.3 months, respectively. Alectinib yielded a median PFS of 18.6 months and OS of 29.8 months in ALK-positive patients, while crizotinib produced a median PFS and OS of 7 months in ROS1-positive patients. The overall response rate was 50% and the disease control rate 84.4%. Although targeted therapies prolonged PFS compared with chemotherapy, this improvement did not translate into a significant OS advantage, likely influenced by retrospective design and treatment crossover. Findings represent real-world outcomes in a molecularly defined subgroup.
- 19 December 2025
- Published by Taylor & Francis in Journal of Chemotherapy
- p. 1-13
The efficacy of targeted therapies in metastatic squamous cell carcinoma of the lung: a Turkish Oncology Group multicentre study
This multicentre real-world study evaluated the efficacy of targeted therapies in Turkish patients with metastatic squamous cell lung carcinoma harbouring driver mutations. Sixty-four patients with alterations such as EGFR, ALK, and ROS1 who received targeted agents were retrospectively analysed. EGFR mutations were most common (67.2%). Among EGFR-TKI-treated patients, median progression-free survival (PFS) and overall survival (OS) were 12.4 and 14.3 months, respectively. Alectinib yielded a median PFS of 18.6 months and OS of 29.8 months in ALK-positive patients, while crizotinib produced a median PFS and OS of 7 months in ROS1-positive patients. The overall response rate was 50% and the disease control rate 84.4%. Although targeted therapies prolonged PFS compared with chemotherapy, this improvement did not translate into a significant OS advantage, likely influenced by retrospective design and treatment crossover. Findings represent real-world outcomes in a molecularly defined subgroup.
- 22 July 2025
- Published by Elsevier in Clinical Lung Cancer
- Vol. 26 (8) , e649-e659
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group
- 22 July 2025
- Published by Elsevier in Clinical Lung Cancer
- Vol. 26 (8) , e649-e659
Real-World Outcomes in BRAF-Mutant Non-small Cell Lung Cancer: A Multicenter Analysis From the Turkish Oncology Group
- Open Access
Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations
Background and Objectives: Despite advances in immunotherapy, predicting survival outcomes in patients with non-small-cell lung cancer (NSCLC) remains challenging. Inflammatory and nutritional indices such as the Prognostic Nutritional Index (PNI), Geriatric Nutritional Risk Index (GNRI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Inflammatory Burden Index (IBI) have emerged as promising prognostic markers associated with overall survival (OS) in NSCLC patients. Materials and Methods: We retrospectively analyzed a total of 196 NSCLC patients treated with second-line nivolumab across multiple centers in Turkey. Of these, 101 patients aged ≥ 65 years were included in the elderly subgroup analysis. PNI, GNRI (in patients aged ≥ 65), and inflammation-based indices were calculated using pre-treatment laboratory values. ROC analysis determined optimal cut-off values. The Kaplan–Meier method and Cox proportional hazards models were used for survival analysis. Results: Median overall survival (OS) was 12.9 months in the full cohort and 12.1 months in patients aged ≥ 65. In univariate analysis, ECOG performance status (0–1), lower NLR (p = 0.02] and elderly patients [HR: 0.45, 95% CI: 0.24–0.84; p = 0.01]. PNI is an independent prognostic biomarker for OS in NSCLC patients treated with immune checkpoint inhibitors. Conclusions: These findings support incorporating simple, cost-effective nutritional indices into clinical decision-making, particularly in elderly patients with NSCLC.
Open AccessPrognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations
Background and Objectives: Despite advances in immunotherapy, predicting survival outcomes in patients with non-small-cell lung cancer (NSCLC) remains challenging. Inflammatory and nutritional indices such as the Prognostic Nutritional Index (PNI), Geriatric Nutritional Risk Index (GNRI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Inflammatory Burden Index (IBI) have emerged as promising prognostic markers associated with overall survival (OS) in NSCLC patients. Materials and Methods: We retrospectively analyzed a total of 196 NSCLC patients treated with second-line nivolumab across multiple centers in Turkey. Of these, 101 patients aged ≥ 65 years were included in the elderly subgroup analysis. PNI, GNRI (in patients aged ≥ 65), and inflammation-based indices were calculated using pre-treatment laboratory values. ROC analysis determined optimal cut-off values. The Kaplan–Meier method and Cox proportional hazards models were used for survival analysis. Results: Median overall survival (OS) was 12.9 months in the full cohort and 12.1 months in patients aged ≥ 65. In univariate analysis, ECOG performance status (0–1), lower NLR (p = 0.02] and elderly patients [HR: 0.45, 95% CI: 0.24–0.84; p = 0.01]. PNI is an independent prognostic biomarker for OS in NSCLC patients treated with immune checkpoint inhibitors. Conclusions: These findings support incorporating simple, cost-effective nutritional indices into clinical decision-making, particularly in elderly patients with NSCLC.
- Open Access
- 1 October 2024
- Published by Wolters Kluwer Health in Indian Journal of Cancer
- Vol. 61 (4) , 789-796
Prognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy
Background: We aimed to investigate the relationship between sarcopenia, which is defined by using psoas muscle index (PMI), and survival outcomes in patients with metastatic renal cell carcinoma (mRCC). Methods: This is a retrospective descriptive study of mRCC treated with first-line anti-vascular endothelial growth factor (anti-VEGF) therapy. The prognostic significance of PMI for progression-free survival (PFS) and overall survival (OS) was evaluated by univariate and multivariate analyses. Additionally, the skeletal muscle index (SMI) was calculated and correlation analysis was performed between PMI and SMI. Results: Eighty-eight patients with a median age of 60 years (interquartile range [IQR], 51–66) were included. Median PFS with first-line treatment was 6 (95% confidence interval [CI]: 2.9–9.03) months and median OS was 17 (95% CI: 10.6–23.03) months in all patients. Mean PMI was 5.71 (standard deviation [SD]: ±1.41) in women and 8.30 (SD: ±2.04) in men. Forty-seven (53.4%) patients according to PMI and 49 (55.6%) patients according to SMI were accepted as sarcopenic. The overall correlation between SMI and PMI was strong (rs = 0.73). PFS was numerically shorter in the low-PMI and low-SMI groups than the high-PMI and high-SMI groups, but it did not reach statistical significance. In univariate analyses, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score, anti-VEGF agent option, PMI, and SMI were significant prognostic factors for OS (P < 0.05 each). In multivariate analyses for OS, while IMDC score (P < 0.001) and PMI (P = 0.04) were significant independent prognostic factors according to multivariate analysis-1, IMDC score (P < 0.001) and SMI (P = 0.01) were significant independent prognostic factors according to multivariate analysis-2. Conclusions: Pretreatment PMI has a strong correlation with SMI and is an independent prognostic factor for OS in patients with mRCC.
- 1 October 2024
- Published by Wolters Kluwer Health in Indian Journal of Cancer
- Vol. 61 (4) , 789-796
Open AccessPrognostic value of psoas muscle index in metastatic renal cell carcinoma patients treated with anti-VEGF therapy
Background: We aimed to investigate the relationship between sarcopenia, which is defined by using psoas muscle index (PMI), and survival outcomes in patients with metastatic renal cell carcinoma (mRCC). Methods: This is a retrospective descriptive study of mRCC treated with first-line anti-vascular endothelial growth factor (anti-VEGF) therapy. The prognostic significance of PMI for progression-free survival (PFS) and overall survival (OS) was evaluated by univariate and multivariate analyses. Additionally, the skeletal muscle index (SMI) was calculated and correlation analysis was performed between PMI and SMI. Results: Eighty-eight patients with a median age of 60 years (interquartile range [IQR], 51–66) were included. Median PFS with first-line treatment was 6 (95% confidence interval [CI]: 2.9–9.03) months and median OS was 17 (95% CI: 10.6–23.03) months in all patients. Mean PMI was 5.71 (standard deviation [SD]: ±1.41) in women and 8.30 (SD: ±2.04) in men. Forty-seven (53.4%) patients according to PMI and 49 (55.6%) patients according to SMI were accepted as sarcopenic. The overall correlation between SMI and PMI was strong (rs = 0.73). PFS was numerically shorter in the low-PMI and low-SMI groups than the high-PMI and high-SMI groups, but it did not reach statistical significance. In univariate analyses, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) risk score, anti-VEGF agent option, PMI, and SMI were significant prognostic factors for OS (P < 0.05 each). In multivariate analyses for OS, while IMDC score (P < 0.001) and PMI (P = 0.04) were significant independent prognostic factors according to multivariate analysis-1, IMDC score (P < 0.001) and SMI (P = 0.01) were significant independent prognostic factors according to multivariate analysis-2. Conclusions: Pretreatment PMI has a strong correlation with SMI and is an independent prognostic factor for OS in patients with mRCC.
- Open Access
- 1 January 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (6) , 1205-1214
Evaluating the performance of the Mskcc gastric cancer survıval calculator in the Turkısh population
Bacground/Aim: The MSKCC(Memorial Sloan Kettering Cancer Center) nomogram was developed to predict survivorship in gastric cancer patients undergoing R0 resection. This study aimed to evaluate the predictive power of this nomogram in the Turkish patient population. Materials and Methods: Gastric cancer patients over 18 years of age who were admitted to our clinic between 2000 and 2019 and underwent primary curative surgery and R0 resection were included in the study. The 5-year and 9-year overall survival rates of 489 patients were analyzed. Real-life survival rates and those calculated with the MSKCC tool were compared in all patients and subgroups. The relationship between variables and survival were analyzed.Results:The 5-year median overall survival observed in all patients was 51.7%, while the 5-year median overall survival calculated with the MSKCC mediator was 48.5%. The difference between expected and observed survival rates were calculated as 3.2%. The ratios were similar and there was no statistically significant difference (p:0.31).The 9-year median overall survival observed in all patients was 41.4%, while the 5-year median overall survival calculated with the MSKCC mediator was 41%. The difference between expected and observed survival rates was calculated as 0.4%. The ratios were similar and there was no statistically significant difference (p:0.9).Conclusion: We found that 5-year and 9-year survival rates estimated by MSKCC toll were correlated with 5-year and 9-year survival rates in real-life data. We believe that the use of the MSKCC prognostic tool in clinical practice should be expanded.
- 1 January 2024
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 54 (6) , 1205-1214
Open AccessEvaluating the performance of the Mskcc gastric cancer survıval calculator in the Turkısh population
Bacground/Aim: The MSKCC(Memorial Sloan Kettering Cancer Center) nomogram was developed to predict survivorship in gastric cancer patients undergoing R0 resection. This study aimed to evaluate the predictive power of this nomogram in the Turkish patient population. Materials and Methods: Gastric cancer patients over 18 years of age who were admitted to our clinic between 2000 and 2019 and underwent primary curative surgery and R0 resection were included in the study. The 5-year and 9-year overall survival rates of 489 patients were analyzed. Real-life survival rates and those calculated with the MSKCC tool were compared in all patients and subgroups. The relationship between variables and survival were analyzed.Results:The 5-year median overall survival observed in all patients was 51.7%, while the 5-year median overall survival calculated with the MSKCC mediator was 48.5%. The difference between expected and observed survival rates were calculated as 3.2%. The ratios were similar and there was no statistically significant difference (p:0.31).The 9-year median overall survival observed in all patients was 41.4%, while the 5-year median overall survival calculated with the MSKCC mediator was 41%. The difference between expected and observed survival rates was calculated as 0.4%. The ratios were similar and there was no statistically significant difference (p:0.9).Conclusion: We found that 5-year and 9-year survival rates estimated by MSKCC toll were correlated with 5-year and 9-year survival rates in real-life data. We believe that the use of the MSKCC prognostic tool in clinical practice should be expanded.
- Open Access
- 1 January 2024
- Published by Wiley in International Journal of Breast Cancer
- Vol. 2024 (1) , 6117394
Neoadjuvant Chemotherapy Shortens the cfDNA Telomere Length in Breast Cancer Patients
Introduction: Cancer is a genetic disease that affects people worldwide, and breast cancer is the most common cancer in women. Studies have been conducted on molecular parameters to predict tumor behavior and develop therapeutic strategies. Telomeres, which are at the end of chromosomes, have been studied for their relationship with breast cancer, but more research is needed to understand their role in the disease. Circulating‐free DNA (cfDNA) is DNA that is free in the bloodstream and is considered a promising target for early cancer detection, treatment response monitoring, and prognosis assessment. This study is aimed at comparing cfDNA telomere length of breast cancer patients and healthy individuals and analyzing the impact of neoadjuvant chemotherapy on telomere length in cfDNA.Materials and Methods: Blood samples were collected from 33 breast cancer patients undergoing neoadjuvant chemotherapy before and after treatment. The quantitative PCR method is used to measure the average telomere lengths.Results: This study found that the telomere length of cfDNA in breast cancer patients before and after treatment is significantly shorter than in the control group. Neoadjuvant chemotherapy is found to shorten the cfDNA telomere length, especially in the treatment‐responsive group.Conclusion: Our study suggests that telomere length in cfDNA may be a useful biomarker for predicting therapy response and possible reoccurrence of the disease in breast cancer patients.
- 1 January 2024
- Published by Wiley in International Journal of Breast Cancer
- Vol. 2024 (1) , 6117394
Open AccessNeoadjuvant Chemotherapy Shortens the cfDNA Telomere Length in Breast Cancer Patients
Introduction: Cancer is a genetic disease that affects people worldwide, and breast cancer is the most common cancer in women. Studies have been conducted on molecular parameters to predict tumor behavior and develop therapeutic strategies. Telomeres, which are at the end of chromosomes, have been studied for their relationship with breast cancer, but more research is needed to understand their role in the disease. Circulating‐free DNA (cfDNA) is DNA that is free in the bloodstream and is considered a promising target for early cancer detection, treatment response monitoring, and prognosis assessment. This study is aimed at comparing cfDNA telomere length of breast cancer patients and healthy individuals and analyzing the impact of neoadjuvant chemotherapy on telomere length in cfDNA.Materials and Methods: Blood samples were collected from 33 breast cancer patients undergoing neoadjuvant chemotherapy before and after treatment. The quantitative PCR method is used to measure the average telomere lengths.Results: This study found that the telomere length of cfDNA in breast cancer patients before and after treatment is significantly shorter than in the control group. Neoadjuvant chemotherapy is found to shorten the cfDNA telomere length, especially in the treatment‐responsive group.Conclusion: Our study suggests that telomere length in cfDNA may be a useful biomarker for predicting therapy response and possible reoccurrence of the disease in breast cancer patients.
- Open Access
Prognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer
Circulating cytokines could be optimal biomarkers for prognostication and management decisions in colorectal cancer (CRC). Chemorefractory CRC patients with available plasma samples were included in this study. In the discovery cohort (n = 85), 182 circulating cytokines were tested with a semi-quantitative multiplex assay, and prognostic cytokines were analyzed in the validation cohort (n = 111) by ELISA. Overall survival (OS) was the primary outcome measure, with the false discovery rate (FDR) method (significance level of <0.01) being used to correct for multiple comparisons. Four cytokines were associated with OS in the discovery cohort: insulin-like growth factor-binding protein 1 (IGFBP-1) (HR 2.1 [95%CI: 1.58–2.79], FDR < 0.001), insulin-like growth factor-binding protein 2 (IGFBP-2) (HR 1.65 [95%CI: 1.28–2.13], FDR = 0.006), serum amyloid A (SAA) (HR 1.84 [95%CI: 1.39–2.43], FDR < 0.001), and angiotensin II (HR 1.65 [95%CI: 1.29–2.1], FDR = 0.006). Of these, IGFBP-1 (HR 2.70 [95%CI: 1.56–4.76], FDR = 0.007) and IGFBP-2 (HR 3.33 [95%CI: 1.64–6.67], FDR = 0.008) were confirmed to be independently associated with OS in the validation cohort. Patients with high concentrations of IGFBP-1 and/or IGFBP-2 had a median OS of 3.0 months as compared with 6.9 months for those with low concentrations of both cytokines (HR 2.44 [95%CI: 1.52–4.0], FDR = 0.002) Validation of circulating IGFBP-1 and IGFBP-2 as independent prognostic biomarkers for chemorefractory CRC in larger, independent series is warranted.
Open AccessPrognostic Value of Circulating Cytokines in Chemorefractory Colorectal Cancer
Circulating cytokines could be optimal biomarkers for prognostication and management decisions in colorectal cancer (CRC). Chemorefractory CRC patients with available plasma samples were included in this study. In the discovery cohort (n = 85), 182 circulating cytokines were tested with a semi-quantitative multiplex assay, and prognostic cytokines were analyzed in the validation cohort (n = 111) by ELISA. Overall survival (OS) was the primary outcome measure, with the false discovery rate (FDR) method (significance level of <0.01) being used to correct for multiple comparisons. Four cytokines were associated with OS in the discovery cohort: insulin-like growth factor-binding protein 1 (IGFBP-1) (HR 2.1 [95%CI: 1.58–2.79], FDR < 0.001), insulin-like growth factor-binding protein 2 (IGFBP-2) (HR 1.65 [95%CI: 1.28–2.13], FDR = 0.006), serum amyloid A (SAA) (HR 1.84 [95%CI: 1.39–2.43], FDR < 0.001), and angiotensin II (HR 1.65 [95%CI: 1.29–2.1], FDR = 0.006). Of these, IGFBP-1 (HR 2.70 [95%CI: 1.56–4.76], FDR = 0.007) and IGFBP-2 (HR 3.33 [95%CI: 1.64–6.67], FDR = 0.008) were confirmed to be independently associated with OS in the validation cohort. Patients with high concentrations of IGFBP-1 and/or IGFBP-2 had a median OS of 3.0 months as compared with 6.9 months for those with low concentrations of both cytokines (HR 2.44 [95%CI: 1.52–4.0], FDR = 0.002) Validation of circulating IGFBP-1 and IGFBP-2 as independent prognostic biomarkers for chemorefractory CRC in larger, independent series is warranted.